Logo image of IUI1.DE

INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis

FRA:IUI1 - Deutsche Boerse Ag - US46120E6023 - Common Stock - Currency: EUR

467.85  -46.55 (-9.05%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to IUI1. IUI1 was compared to 55 industry peers in the Health Care Equipment & Supplies industry. IUI1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IUI1 is valued quite expensive, but it does show an excellent growth. This makes IUI1 very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

IUI1 had positive earnings in the past year.
In the past year IUI1 had a positive cash flow from operations.
IUI1 had positive earnings in each of the past 5 years.
In the past 5 years IUI1 always reported a positive cash flow from operatings.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

1.2 Ratios

With an excellent Return On Assets value of 12.39%, IUI1 belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
IUI1's Return On Equity of 14.05% is amongst the best of the industry. IUI1 outperforms 87.27% of its industry peers.
The Return On Invested Capital of IUI1 (10.01%) is better than 85.45% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is in line with the industry average of 8.28%.
The 3 year average ROIC (9.61%) for IUI1 is below the current ROIC(10.01%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.39%
ROE 14.05%
ROIC 10.01%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.18%
ROE(5y)12.95%
ROIC(3y)9.61%
ROIC(5y)9.32%
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

The Profit Margin of IUI1 (27.81%) is better than 94.55% of its industry peers.
In the last couple of years the Profit Margin of IUI1 has declined.
IUI1's Operating Margin of 28.14% is amongst the best of the industry. IUI1 outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of IUI1 has declined.
Looking at the Gross Margin, with a value of 67.46%, IUI1 is in the better half of the industry, outperforming 70.91% of the companies in the same industry.
In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
Industry RankSector Rank
OM 28.14%
PM (TTM) 27.81%
GM 67.46%
OM growth 3Y-4.3%
OM growth 5Y-1.74%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
Compared to 1 year ago, IUI1 has more shares outstanding
Compared to 5 years ago, IUI1 has more shares outstanding
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.12
WACC8.96%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

IUI1 has a Current Ratio of 5.22. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
IUI1's Current ratio of 5.22 is amongst the best of the industry. IUI1 outperforms 92.73% of its industry peers.
A Quick Ratio of 4.54 indicates that IUI1 has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.54, IUI1 belongs to the top of the industry, outperforming 94.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.22
Quick Ratio 4.54
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.37% over the past year.
The Earnings Per Share has been growing by 11.48% on average over the past years. This is quite good.
IUI1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.24%.
IUI1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.27% yearly.
EPS 1Y (TTM)28.37%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%38.12%
Revenue 1Y (TTM)17.24%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%25.16%

3.2 Future

The Earnings Per Share is expected to grow by 14.44% on average over the next years. This is quite good.
IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.11% yearly.
EPS Next Y12.03%
EPS Next 2Y14.8%
EPS Next 3Y15.12%
EPS Next 5Y14.44%
Revenue Next Year17.28%
Revenue Next 2Y16.4%
Revenue Next 3Y15.94%
Revenue Next 5Y14.11%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

IUI1 is valuated quite expensively with a Price/Earnings ratio of 69.31.
Compared to the rest of the industry, the Price/Earnings ratio of IUI1 is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 29.35. IUI1 is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 61.85, which means the current valuation is very expensive for IUI1.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 60.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, IUI1 is valued quite expensively.
Industry RankSector Rank
PE 69.31
Fwd PE 61.85
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 60.00% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as IUI1.
Industry RankSector Rank
P/FCF 138.95
EV/EBITDA 60.46
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IUI1 may justify a higher PE ratio.
A more expensive valuation may be justified as IUI1's earnings are expected to grow with 15.12% in the coming years.
PEG (NY)5.76
PEG (5Y)6.04
EPS Next 2Y14.8%
EPS Next 3Y15.12%

More info and screens

0

5. Dividend

5.1 Amount

IUI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTUITIVE SURGICAL INC

FRA:IUI1 (3/7/2025, 7:00:00 PM)

467.85

-46.55 (-9.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-23 2025-01-23/amc
Earnings (Next)04-16 2025-04-16/amc
Inst Owners89.44%
Inst Owner ChangeN/A
Ins Owners0.5%
Ins Owner ChangeN/A
Market Cap166.86B
Analysts79.49
Price Target613.78 (31.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.57%
Min EPS beat(2)10.37%
Max EPS beat(2)20.76%
EPS beat(4)4
Avg EPS beat(4)12.24%
Min EPS beat(4)4.44%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)7.68%
EPS beat(12)10
Avg EPS beat(12)4.92%
EPS beat(16)13
Avg EPS beat(16)7.19%
Revenue beat(2)1
Avg Revenue beat(2)2.49%
Min Revenue beat(2)-0.14%
Max Revenue beat(2)5.12%
Revenue beat(4)1
Avg Revenue beat(4)1.04%
Min Revenue beat(4)-0.76%
Max Revenue beat(4)5.12%
Revenue beat(8)3
Avg Revenue beat(8)0.53%
Revenue beat(12)5
Avg Revenue beat(12)0%
Revenue beat(16)7
Avg Revenue beat(16)1.66%
PT rev (1m)1.23%
PT rev (3m)16.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.11%
EPS NY rev (1m)0.76%
EPS NY rev (3m)2.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.45%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.7%
Valuation
Industry RankSector Rank
PE 69.31
Fwd PE 61.85
P/S 21.69
P/FCF 138.95
P/OCF 75.02
P/B 10.96
P/tB 11.2
EV/EBITDA 60.46
EPS(TTM)6.75
EY1.44%
EPS(NY)7.56
Fwd EY1.62%
FCF(TTM)3.37
FCFY0.72%
OCF(TTM)6.24
OCFY1.33%
SpS21.57
BVpS42.69
TBVpS41.79
PEG (NY)5.76
PEG (5Y)6.04
Profitability
Industry RankSector Rank
ROA 12.39%
ROE 14.05%
ROCE 14.22%
ROIC 10.01%
ROICexc 21.5%
ROICexgc 22.52%
OM 28.14%
PM (TTM) 27.81%
GM 67.46%
FCFM 15.61%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.18%
ROE(5y)12.95%
ROIC(3y)9.61%
ROIC(5y)9.32%
ROICexc(3y)17.26%
ROICexc(5y)16.59%
ROICexgc(3y)18.14%
ROICexgc(5y)17.56%
ROCE(3y)13.65%
ROCE(5y)13.23%
ROICexcg growth 3Y10.09%
ROICexcg growth 5Y3.3%
ROICexc growth 3Y10.33%
ROICexc growth 5Y3.99%
OM growth 3Y-4.3%
OM growth 5Y-1.74%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 222.37%
Cap/Sales 13.3%
Interest Coverage 250
Cash Conversion 84.73%
Profit Quality 56.14%
Current Ratio 5.22
Quick Ratio 4.54
Altman-Z N/A
F-Score7
WACC8.96%
ROIC/WACC1.12
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.37%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%38.12%
EPS Next Y12.03%
EPS Next 2Y14.8%
EPS Next 3Y15.12%
EPS Next 5Y14.44%
Revenue 1Y (TTM)17.24%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%25.16%
Revenue Next Year17.28%
Revenue Next 2Y16.4%
Revenue Next 3Y15.94%
Revenue Next 5Y14.11%
EBIT growth 1Y32.03%
EBIT growth 3Y8.64%
EBIT growth 5Y11.3%
EBIT Next Year37.81%
EBIT Next 3Y24.38%
EBIT Next 5Y19.91%
FCF growth 1Y73.93%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y33.15%
OCF growth 3Y4.95%
OCF growth 5Y8.61%